Evidence map›Paper›PMID 39495775›Full record

ArticleJournal of cellular and molecular medicine2024

Downregulation of GLYAT correlates with tumour progression and poor prognosis in hepatocellular carcinoma.

Fengchen Jiang, Shuiping Zhou, Chuanlong Xia, Jiale Lu, Bin Wang, Xiaowei Wang, Jiandong Shen, Wei Ding, Mengjie Yin, Feng Dai and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cellular and molecular medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Structure of Bovine GlycineBiochemistry · 2025
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Fengchen JiangDepartment of Interventional Angiology, Affiliated Nantong Hospital 3 of Nantong University, Nantong, China.ORCID 0000-0002-8170-4274
Shuiping ZhouDepartment of Interventional Angiology, Affiliated Nantong Hospital 3 of Nantong University, Nantong, China.
Chuanlong XiaDepartment of Interventional Angiology, Affiliated Nantong Hospital 3 of Nantong University, Nantong, China.
Jiale LuDepartment of Interventional Angiology, Affiliated Nantong Hospital 3 of Nantong University, Nantong, China.
Bin WangDepartment of Interventional Angiology, Affiliated Nantong Hospital 3 of Nantong University, Nantong, China.
Xiaowei WangDepartment of Interventional Angiology, Affiliated Nantong Hospital 3 of Nantong University, Nantong, China.
Jiandong ShenDepartment of Interventional Angiology, Affiliated Nantong Hospital 3 of Nantong University, Nantong, China.
Wei DingDepartment of Interventional Angiology, Affiliated Nantong Hospital 3 of Nantong University, Nantong, China.
Mengjie YinDepartment of Interventional Angiology, Affiliated Nantong Hospital 3 of Nantong University, Nantong, China.
Feng DaiDepartment of Interventional Angiology, Affiliated Nantong Hospital 3 of Nantong University, Nantong, China.
Shouzhong FuDepartment of Interventional Angiology, Affiliated Nantong Hospital 3 of Nantong University, Nantong, China.

Funding

Nantong Science and Technology Project JCZ2022024Nantong Science and Technology Project MS12021034Nantong Science and Technology Project MSZ2023020
6 · The paper itself

Abstract

Glycine N-acyltransferase (GLYAT), known to influence glycine metabolism, has been implicated in the progression of various malignant tumours. However, its clinical relevance in hepatocellular carcinoma (HCC) remains unexplored. Here, GLYAT expression levels in HCC tissues were significantly reduced compared to normal liver tissues. Similarly, GLYAT expression levels in Huh 7, HepG2, PLC and SK-HEP1 were lower than those in LO2. Receiver operating characteristic curve analysis demonstrated that GLYAT exhibited good diagnostic performance for HCC. Kaplan-Meier analyses suggested that decreased GLYAT expression was correlated with poorer progress in HCC. Low GLYAT expression was significantly associated with gender and histologic grade. Multivariate Cox regression analysis identified low GLYAT expression and T stage as independent prognostic factors. Nomograms based on GLYAT mRNA expression and T stage showed good concordance with actual survival rates at 1, 2, 3 and 5 years. Moreover, GLYAT downregulation in the Huh 7 cell line enhanced cell proliferation, invasion and migration abilities, while GLYAT overexpression in the HepG2 cell line inhibited these abilities. HCC patients with low GLYAT expression exhibited a predisposition to immune escape and poor response to immunotherapy. This research revealed that GLYAT holds promise as both a prognostic biomarker and a potential therapeutic target in HCC.

Indexed as

Carcinoma, HepatocellularCell MovementCell ProliferationDisease ProgressionDown-RegulationGene Expression Regulation, NeoplasticLiver NeoplasmsAcyltransferasesAgedBiomarkers, TumorCell Line, TumorFemaleHep G2 CellsHumansKaplan-Meier EstimateMaleAcyltransferasesBiomarkers, TumorGLYAThepatocellular carcinomaimmunotherapyprognosistumour progression

Identifiers

PMID39495775
PMCPMC11534071

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.